Bayer Ag · XETR:BAYN

Bayer — 23rd European Society of Retina Specialists (EURETINA) Congress 2023

11 slides from Bayer's conference presentation, October 2023

  1. Slide 1: Two-year results from the eight highest recruiting countries in the XTEND study

    Two-year results from the eight highest recruiting countries included in the global observational XTEND study of real-world proactive regimens with intravitreal aflibercept in patients with nAMD Presented at the 23rd European Society of Retina Specialists (EURETINA) Congress, Amsterdam, Netherlands,

  2. Slide 2: Disclosures

    Disclosures Presenting author Jean-François Korobelnik: Consultant for AbbVie, Apellis, Bayer, Janssen, NanoRetina, Roche, Théa Pharmaceuticals, and Carl Zeiss Meditec AG; member of a data safety monitoring board or advisory board for Alexion, Novo Nordisk, and Oxular. Co-author group VC: Grants fro

  3. Slide 3: Introduction

    Introduction Treat-and-extend is a proactive, individualized treatment regimen that is used to minimize the risk of disease recurrence, whilst maintaining visual gains and reducing treatment burden associated with anti-VEGF therapy XTEND? is an ongoing, 36-month, multicenter, observational, prospect

  4. Slide 4: XTEND (NCT03939767) study design and patient demographics

    XTEND (NCT03939767) study design and patient demographics Primary endpoint: Mean change in BCVA (ETDRS letters) from baseline to Month 12

  5. Slide 5: Patient baseline demographics

    Patient baseline demographics

  6. Slide 6: Functional and anatomic outcomes by Month

    Functional and anatomic outcomes by Month 24 ge 80 Baseline Month 12 # Month 24 2 70 & @ w 60 wo a“ ee 2 50 | , Across the eight countries included in this we 40 y y analysis, mean change (95% Cl) in CST x y , from baseline to 12 months was 3 30 1 -79 (-110, -47) to -125 (-161, -90) ym, 2 20 L y and

  7. Slide 7: Visual outcomes at 24 months stratified by baseline visual acuity

    Visual outcomes at 24 months stratified by baseline visual acuity

  8. Slide 8: Treatment exposure – number of injections

    Treatment exposure – number of injections

  9. Slide 9: Treatment exposure – last treatment interval up to 24 months

    Treatment exposure – last treatment interval up to 24 months

  10. Slide 10: Conclusions

    Conclusions In the ongoing XTEND study, the majority of patients enrolled with high baseline BCVA, suggesting early initiation of treatment for nAMD There was a broad range of baseline BCVA and injection numbers across the "| eight countries that enrolled 250 patients, which could be attributed to d

  11. Slide 11: Thank you to all XTEND patients and investigators

    Thank you to all XTEND patients and investigators

Bayer — 23rd European Society of Retina Specialists (EURETINA) Congress 2023 on 6ix